Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates from Hubei Province, China

Brazilian Journal of Infectious Diseases

Volumn 16, Issue 2, 2012, Pages 136-141

  Chen, Jun ^a,b   Chen, Zhifei ^b   Li, Yuanyuan ^a   Xia, Wei ^a   Chen, Xi ^a   Chen, Tian ^a   Zhou, Liping ^c   Xu, Bin ^a   Xu, Shunqing ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Wuhan Tuberculosis Prevention and Treatment Center   (China)

^c DEPARTMENT OF HEALTH   (Hong Kong)

Author keywords

DNA mutational analysis; Fluoroquinolones; Mycobacterium tuberculosis

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; MOXIFLOXACIN; OFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHINA; CODON; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; GYRA GENE; GYRB GENE; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE;

EID: 85027948475     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/S1413-8670(12)70294-5     Document Type: Article

References (28)

1. Multidrug and extensively drugresistant TB (M/XDR-TB): 2010 global report on surveillance and response 2010, World Health Organization, World Health Organization, Geneva.
2. Guidelines for the programmatic management of drug resistant tuberculosis 2006, World Health Organization, World Health Organization, Geneva.
3. Huang T.S., Kunin C.M., Shin-Jung Lee, et al. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicrob Chemother 2005, 56:1058-1062.
4. Jabeen K., Shakoor S., Chishti S., et al. Fluoroquinoloneresistant Mycobacterium tuberculosis, Pakistan, 2005-2009. Emerg Infect Dis 2011, 17:564-566.
5. Shi R., Zhang J., Li C., et al. Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing. J Clin Microbiol 2006, 44:4566-4568.
6. Johnston J.C., Shahidi N.C., Sadatsafavi M., et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009, 4:e6914.
7. Gillespie S.H., Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother 1999, 44:393-395.
8. Peloquin C.A., Hadad D.J., Molino L.P., et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008, 52:852-857.
9. Xu C., Kreiswirth B.N., Sreevatsan S., et al. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J Infect Dis 1996, 174:1127-1130.
10. Guidelines for drug susceptibility testing for second-line anti-tuberculosis drugs for DOST-plus 2001, World Health Organization, World Health Organization, Geneva.
11. Martin A., Palomino J.C., Portaels F. Rapid detection of ofloxacin resistance in Mycobacterium tuberculosis by two lowcost colorimetric methods: resazurin and nitrate reductase assays. J Clin Microbiol 2005, 43:1612-1616.
12. Cui Z., Wang J., Lu J., et al. Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009. BMC Infect Dis 2011, 11:78.
13. Mokrousov I., Otten T., Manicheva O., et al. Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia. Antimicrob Agents Chemother 2008, 52:2937-2939.
14. Von Groll A., Martin A., Jureen P., et al. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother 2009, 53:4498-4500.
15. Wang J.Y., Lee L.N., Lai H.C., et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 2007, 59:860-865.
16. Yin X., Yu Z. Mutation characterization of gyrA and gyrB genes in levofloxacin-resistant Mycobacterium tuberculosis clinical isolates from Guangdong Province in China. J Infect 2010, 61:150-154.
17. Cheng A.F., Yew W.W., Chan E.W., et al. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 2004, 48:596-601.
18. Jarlier V., Nikaido H. Mycobacterial cell wall: structure and role in natural resistance to antibiotics. FEMS Microbiol Lett 1994, 123:11-18.
19. Escribano I., Rodriguez J.C., Llorca B., et al. Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid. Chemotherapy 2007, 53:397-401.
20. Gupta A.K., Katoch V.M., Chauhan D.S., et al. Microarray analysis of efflux pump genes in multidrug-resistant Mycobacterium tuberculosis during stress induced by common antituberculous drugs. Microb Drug Resist 2010, 16:21-28.
21. Kocagoz T., Hackbarth C.J., Unsal I., et al. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 1996, 40:1768-1774.
22. Sun Z., Zhang J., Zhang X., et al. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Int J Antimicrob Agents 2008, 31:115-121.
23. Hauck Y., Fabre M., Vergnaud G., et al. Comparison of two commercial assays for the characterization of rpoB mutations in Mycobacterium tuberculosis and description of new mutations conferring weak resistance to rifampicin. J Antimicrob Chemother 2009, 64:259-262.
24. Kim S.Y., Park Y.J., Kim W.I., et al. Molecular analysis of isoniazid resistance in Mycobacterium tuberculosis isolates recovered from South Korea. Diagn Microbiol Infect Dis 2003, 47:497-502.
25. Lu T., Zhao X., Drlica K. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group. Antimicrob Agents Chemother 1999, 43:2969-2974.
26. Lu T., Zhao X., Li X., et al. Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. Antimicrob Agents Chemother 2001, 45:2703-2709.
27. Dong Y., Zhao X., Kreiswirth B.N., et al. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000, 44:2581-2584.
28. Poissy J., Aubry A., Fernandez C., et al. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother 2010, 54:4765-4771.